Image 5_Exploratory spatial transcriptomic profiling of peritumoral Th2 immune polarization in HPV-positive oropharyngeal cancer.jpeg

Image 5_Exploratory spatial transcriptomic profiling of peritumoral Th2 immune polarization in HPV-positive oropharyngeal cancer.jpeg

Introduction<p>Oropharyngeal squamous cell carcinoma (OPC) associated with high-risk human papillomavirus (HPV), particularly HPV-16, generally shows favorable outcomes yet paradoxically exhibits a high incidence of early lymphatic metastasis. The immune mechanisms underlying this phenomenon r...

Description complète

Enregistré dans:

Détails bibliographiques
Auteur principal:	Naohiro Wakisaka (407153) (author)
Autres auteurs:	Makiko Moriyama-Kita (833101) (author), Satoru Kondo (407152) (author), Eiji Kobayashi (107710) (author), Takayoshi Ueno (457816) (author), Yosuke Nakanishi (407151) (author), Kazuhira Endo (407155) (author), Hisashi Sugimoto (2146888) (author), Tomokazu Yoshizaki (407160) (author)
Publié:	2025
Sujets:	Oncology and Carcinogenesis not elsewhere classified HPV-positive oropharyngeal cancer palatine tonsil spatial transcriptomics tumor immune microenvironment Th2 immunity lymphatic metastasis eosinophils and mast cells estrogen signaling
Tags:	Ajouter un tag Pas de tags, Soyez le premier à ajouter un tag!

Documents similaires

Image 4_Exploratory spatial transcriptomic profiling of peritumoral Th2 immune polarization in HPV-positive oropharyngeal cancer.jpeg
par: Naohiro Wakisaka (407153)
Publié: (2025)

Image 2_Exploratory spatial transcriptomic profiling of peritumoral Th2 immune polarization in HPV-positive oropharyngeal cancer.jpeg
par: Naohiro Wakisaka (407153)
Publié: (2025)

Image 3_Exploratory spatial transcriptomic profiling of peritumoral Th2 immune polarization in HPV-positive oropharyngeal cancer.jpeg
par: Naohiro Wakisaka (407153)
Publié: (2025)

Image 1_Exploratory spatial transcriptomic profiling of peritumoral Th2 immune polarization in HPV-positive oropharyngeal cancer.jpeg
par: Naohiro Wakisaka (407153)
Publié: (2025)

Table 1_Exploratory spatial transcriptomic profiling of peritumoral Th2 immune polarization in HPV-positive oropharyngeal cancer.xlsx
par: Naohiro Wakisaka (407153)
Publié: (2025)

Table 1_Immune responses in pulmonary sarcoidosis following COVID-19.docx
par: Anna Starshinova (22571846)
Publié: (2025)

Substrate recognition diversity and transport dynamics of ABCC1
par: Pu Gao (14074898)
Publié: (2025)

Supplementary Figure S1 from Negative Predictive Value of Circulating Tumor Tissue Modified Viral (TTMV)-HPV DNA for HPV-driven Oropharyngeal Cancer Surveillance
par: Glenn J. Hanna (15036909)
Publié: (2025)

Data Sheet 10_LL37-driven mast cell degranulation and inflammation in rosacea via TLR2/JAK2/STAT3 axis.zip
par: Huiping Fan (13921872)
Publié: (2025)

Data Sheet 9_LL37-driven mast cell degranulation and inflammation in rosacea via TLR2/JAK2/STAT3 axis.zip
par: Huiping Fan (13921872)
Publié: (2025)

Data Sheet 8_LL37-driven mast cell degranulation and inflammation in rosacea via TLR2/JAK2/STAT3 axis.zip
par: Huiping Fan (13921872)
Publié: (2025)

Data Sheet 6_LL37-driven mast cell degranulation and inflammation in rosacea via TLR2/JAK2/STAT3 axis.zip
par: Huiping Fan (13921872)
Publié: (2025)

Data Sheet 7_LL37-driven mast cell degranulation and inflammation in rosacea via TLR2/JAK2/STAT3 axis.zip
par: Huiping Fan (13921872)
Publié: (2025)

Data Sheet 5_LL37-driven mast cell degranulation and inflammation in rosacea via TLR2/JAK2/STAT3 axis.zip
par: Huiping Fan (13921872)
Publié: (2025)

Data Sheet 4_LL37-driven mast cell degranulation and inflammation in rosacea via TLR2/JAK2/STAT3 axis.zip
par: Huiping Fan (13921872)
Publié: (2025)

Data Sheet 3_LL37-driven mast cell degranulation and inflammation in rosacea via TLR2/JAK2/STAT3 axis.zip
par: Huiping Fan (13921872)
Publié: (2025)

Data Sheet 2_LL37-driven mast cell degranulation and inflammation in rosacea via TLR2/JAK2/STAT3 axis.zip
par: Huiping Fan (13921872)
Publié: (2025)

Data Sheet 1_LL37-driven mast cell degranulation and inflammation in rosacea via TLR2/JAK2/STAT3 axis.zip
par: Huiping Fan (13921872)
Publié: (2025)

Microbiome Mediated Immune Crosstalk on the Gut-Thyroid Axis in Autoimmune Thyroid Disease
par: Mubeen Hussein Arawker (12965954)
Publié: (2025)

Adverse events during follow-up period in Phase III non-inferiority clinical trial of SnaFab compared to Razi antivenom in snakebites.
par: Seyed Reza Mousavi (13223324)
Publié: (2025)

Demographic information and clinical presentation of victims in Phase III non-inferiority clinical trial of SnaFab compare to Razi antivenom in snakebites.
par: Seyed Reza Mousavi (13223324)
Publié: (2025)

Snakebite severity classification in clinical trial of SnaFab vs. Razi antivenom in snakebite victims [14,57,58].
par: Seyed Reza Mousavi (13223324)
Publié: (2025)

The non-inferiority margin in Phase III clinical trial of SnaFab compared to Razi antivenom in snakebites.
par: Seyed Reza Mousavi (13223324)
Publié: (2025)

Consort Chart of Phase III clinical trial of SnaFab compare to Razi antivenom in snakebites.
par: Seyed Reza Mousavi (13223324)
Publié: (2025)

Survey of dysphagia protocol use (Carnaby et al., 2025)
par: Giselle D. Carnaby (22575401)
Publié: (2025)

Image 2_Immune-related RELT drives clear cell renal cell carcinoma progression through JAK/STAT signaling pathway activation.tiff
par: Yini Wang (410389)
Publié: (2025)

Image 1_Immune-related RELT drives clear cell renal cell carcinoma progression through JAK/STAT signaling pathway activation.tiff
par: Yini Wang (410389)
Publié: (2025)

Lipids attribution for controls and dengue groups according with Lipid Maps database, obtained via exploratory metabolomics from human serum.
par: Ricardo E. Correa Fierro (22676430)
Publié: (2025)

Table 1_Immune checkpoint inhibitor therapy in advanced cancer: clinical association of irAEs type, inflammatory markers and efficacy.docx
par: Mengying Qian (2541466)
Publié: (2025)

Table S2 from Hydrogen Sulfide Creates a Favorable Immune Microenvironment for Colon Cancer
par: Taohua Yue (14963045)
Publié: (2025)

Supplementary Table from CDK2 Inhibition Enhances Antitumor Immunity by Increasing IFN Response to Endogenous Retroviruses
par: Yu Chen (1234761)
Publié: (2025)

Supplementary Table from CDK2 Inhibition Enhances Antitumor Immunity by Increasing IFN Response to Endogenous Retroviruses
par: Yu Chen (1234761)
Publié: (2025)

Supplementary Table from CDK2 Inhibition Enhances Antitumor Immunity by Increasing IFN Response to Endogenous Retroviruses
par: Yu Chen (1234761)
Publié: (2025)

Supplementary Table from CDK2 Inhibition Enhances Antitumor Immunity by Increasing IFN Response to Endogenous Retroviruses
par: Yu Chen (1234761)
Publié: (2025)

Supplementary Data from PP2Ac Deficiency Enhances Tumor Immunogenicity by Activating STING–Type I Interferon Signaling in Glioblastoma
par: Isha Mondal (16721699)
Publié: (2025)

Supplementary Data from Attenuation of Sialylation Augments Antitumor Immunity and Improves Response to Immunotherapy in Ovarian Cancer
par: Kankan Cao (16437263)
Publié: (2025)

Supplementary Table S1 from Intratumoral CD16<sup>+</sup> Macrophages Are Associated with Clinical Outcomes of Patients with Metastatic Melanoma Treated with Combination Anti-PD-1 and Anti-CTLA-4 Therapy
par: Hansol Lee (15054787)
Publié: (2025)

Supplementary Table S2 from Intratumoral CD16<sup>+</sup> Macrophages Are Associated with Clinical Outcomes of Patients with Metastatic Melanoma Treated with Combination Anti-PD-1 and Anti-CTLA-4 Therapy
par: Hansol Lee (15054787)
Publié: (2025)

Supplementary Table S3 from Intratumoral CD16<sup>+</sup> Macrophages Are Associated with Clinical Outcomes of Patients with Metastatic Melanoma Treated with Combination Anti-PD-1 and Anti-CTLA-4 Therapy
par: Hansol Lee (15054787)
Publié: (2025)

Supplementary Table S4 from Intratumoral CD16<sup>+</sup> Macrophages Are Associated with Clinical Outcomes of Patients with Metastatic Melanoma Treated with Combination Anti-PD-1 and Anti-CTLA-4 Therapy
par: Hansol Lee (15054787)
Publié: (2025)

Cannot write session to /tmp/vufind_sessions/sess_5cu71cr02tgo80oap8shs86huu